semaglutide and type 1 diabetes tirzepatide treatment leads to weight loss in Is Semaglutide GLP-1 the Same
Description
The study also found that cardiometabolic risks, including dyslipidemia and hypertension, rose more rapidly in the younger population
Quick Answer: GLP-1 medications show clinically meaningful average weight loss in large-scale peer-reviewed trials - approximately 14.9% for semaglutide (STEP 1) and up to 20.9% for tirzepatide (SURMOUNT-1) under trial conditions
Complete blood count catches elevated hematocrit (red blood cell concentration), which can increase stroke and clot risk if unaddressed
Prescribed by licensed providers and delivered to your door
[DOI] [PubMed] [Google Scholar] Rossi GCM, Gandini Wheeler-Kingshott CAM, Toosy A
